Kohlberg Kravis Roberts & Co. L.P. Coherus Bio Sciences, Inc. Transaction History
Kohlberg Kravis Roberts & Co. L.P.
- $1.73 Billion
- Q2 2024
A detailed history of Kohlberg Kravis Roberts & Co. L.P. transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Kohlberg Kravis Roberts & Co. L.P. holds 3,036,076 shares of CHRS stock, worth $2.03 Million. This represents 0.3% of its overall portfolio holdings.
Number of Shares
3,036,076
Previous 3,036,076
-0.0%
Holding current value
$2.03 Million
Previous $7.26 Million
27.62%
% of portfolio
0.3%
Previous 0.31%
Shares
2 transactions
Others Institutions Holding CHRS
# of Institutions
140Shares Held
76.8MCall Options Held
79.1KPut Options Held
100K-
Black Rock Inc. New York, NY11.8MShares$7.87 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.6MShares$7.1 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY10.4MShares$6.97 Million0.53% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.84MShares$1.91 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.38MShares$1.6 Million0.0% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $52.1M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...